Australia, Dec. 10 -- Avidity Biosciences Inc., owns the trademark (2475598) for 'DEL-DESIRAN' till Aug. 20, 2034.
Status: registered:
Registered/protected
Classes: 5 [Oligonucleotide-conjugate based therapies, oligonucleotide-antibody conjugate based therapies, and oligonucleotide-antibody fragment conjugate based therapies for the treatment of metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy, genitourinary, oncological, hepatological, ophthalmic, respiratory, central and/or peripheral neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders], 42 [Providing medical and scientific research information in the fields of pharmaceuticals and biotechnology], 5 [Oligonucleotide-conjugate based therapies, oligonucleotide-antibody conjugate based therapies, and oligonucleotide-antibody fragment conjugate based therapies for the treatment of metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy, genitourinary, oncological, hepatological, ophthalmic, respiratory, central and/or peripheral neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders] and 42 [Providing medical and scientific research information in the fields of pharmaceuticals and biotechnology]
Type of Mark: Word
Date of Acceptance: Oct. 2
Registration Advertised: Dec. 9
For further details contact Davies Collison Cave Pty. Ltd. .
The original document can be viewed at: https://search.ipaustralia.gov.au/trademarks/search/view/2475598.
Disclaimer: Curated by HT Syndication.
